RT Journal Article
SR Electronic
T1 Worldwide routine immunisation coverage regressed during the first year of the COVID-19 pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.03.21267195
DO 10.1101/2021.12.03.21267195
A1 Evans, Beth
A1 Jombart, Thibaut
YR 2021
UL http://medrxiv.org/content/early/2021/12/05/2021.12.03.21267195.abstract
AB We modelled historical, country-specific routine immunisation trends using publicly available vaccination coverage data for diphtheria, tetanus and pertussis-containing vaccine first-dose (DTP1) and third-dose (DTP3) from 2000 to 2019. We evaluate changes in coverage in 2020 by comparing model predictions to WUENIC-reported coverage. We report a 2.9% (95%CI: [2.2%; 3.6%]) global decline in DTP3 coverage, and important increases in missed immunisations in some countries with middle-income countries, and the Americas, being most affected.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTJ receives funding from the Global Challenges Research Fund (GCRF) project RECAP managed through RCUK and ESRC (ES/P010873/1), from the National Institute for Health Research - Health Protection Research Unit for Modelling Methodology, and from the Medical Research Council (grant number MC_PC_19065). These funders had no role in the design and conduct of this study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. BE is an MSc student at the London School of Hygiene and Tropical Medicine, and received no funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study use publicly available datasets. All data and reproducible analyses are available online at- https://github.com/bevans249/modelling_covid_imact_RI https://github.com/bevans249/modelling_covid_imact_RI https://doi.org/10.5281/zenodo.5750111